1
|
Gioviale MC, Damiano G, Lombardo C, Maione C, Buscemi G, Lo Monte AI. Bone resorption in kidney transplant recipients. Transplant Proc 2015; 41:1170-4. [PMID: 19460508 DOI: 10.1016/j.transproceed.2009.03.043] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Early diagnosis of persistent hyperparathyroidism (HP) following kidney transplantation may prevent worsening of osteodystrophy and potential damage to the graft. We evaluated the utility of collagen pyridinoline (PYD) and deoxypyridinoline (DPD) urinary cross-links beyond the common HP markers to evaluate 70 selected stable recipients between 1997 and 2006 who were divided into 2 group depending on the immunosuppressive protocol. All patients showed elevated levels of urinary cross-links even though calcemia and phosphoremia values were normal. Their mean creatinine level was slightly increased. Data were assessed as mean values +/- SD. All variables underwent a correlation matrix analysis and a stepwise regression, with posttransplant intact parathyroid hormone (iPTH) as the dependent variable and other variables as regressors. A statistically significant correlation was observed between PYD and alkaline phosphatase (ALP; P = .0026, r = .41); PYD and DPD (P = .015, r = .34); pre- and posttransplant iPTH (P = .024, r = .31); and creatinine and ALP (P = .024, r = .31). Taking the groups separately, there were significant correlations between PYD and ALP (P = .0076, r = .42); PYD and DPD (P = .017, r = .38); ALP and posttransplant iPTH (P = .038, r = .33); osteocalcin (OC) and posttransplant iPTH (P = .048, r = .32); and pre- and posttransplant iPTH (P = .019, r = .37) among subjects in the first group, whereas subjects in the second group showed a correlation between posttransplant iPTH and age at transplantation (P = .032, r = .61). In conclusion, we showed that urinary cross-links may be helpful to reveal bone resorption in kidney recipients when usual bone metabolism parameters do not demonstrate hyperparathyroidism.
Collapse
Affiliation(s)
- M C Gioviale
- Department of General Surgery, Urgency, and Organ Transplantation, University of Palermo, School of Medicine, Palermo, Italy
| | | | | | | | | | | |
Collapse
|
2
|
Brown JE, Coleman RE. Biomarkers of bone turnover in oncology: applications in diagnosis and treatment. ACTA ACUST UNITED AC 2010; 4:125-38. [DOI: 10.1517/17530050903473147] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
3
|
|
4
|
Belstra BA, Flowers WL, Croom WJ, Degroot J, See MT. Urinary excretion of collagen degradation markers by sows during postpartum uterine involution. Anim Reprod Sci 2005; 85:131-45. [PMID: 15556316 DOI: 10.1016/j.anireprosci.2004.04.035] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2004] [Revised: 04/21/2004] [Accepted: 04/21/2004] [Indexed: 11/22/2022]
Abstract
Incomplete uterine involution is the putative cause of the increased embryo mortality and reproductive failure often exhibited by sows that lactate for less than 21 days. Since such short lactation lengths are common in American swine production, an effective technique to monitor the postpartum involution process and test this hypothesis might be valuable. Rapid and extensive catabolism of uterine collagen is essential for normal postpartum involution. The objective of this study was to characterize postpartum excretion of two biochemical markers of collagen degradation. In experiment I, urine samples were collected from five sows every other day from the day before parturition (day -1), through a 21-day lactation, to day 8 postweaning. The collagen crosslinks hydroxylysyl pyridinoline (HP), which is present in many tissues, and lysyl pyridinoline (LP), which is primarily concentrated in bone, were assayed by both ELISA and HPLC. Urinary levels of both free (ELISA) and total (HPLC) HP and LP increased (P < 0.001) approximately two-fold during lactation. The mean molar ratio of total HP:LP increased (P < 0.001) from 6.6 +/- 1.6 at day 1 to a maximum of 10.2 +/- 1.5 at day 7 postpartum and averaged 9.1 +/- 0.3 for the entire sampling period. These data are consistent with a postpartum increase of soft tissue collagen catabolism since bone has a low HP:LP ratio of 4 and soft tissues like the uterus have a high HP:LP ratio of >/=20 because they contain only trace amounts of LP. Since HPLC (total) and ELISA (free) crosslinks estimates were highly correlated (r = 0.85-0.91, P < 0.001) in experiment I, only the less technical ELISA technique was used in experiment II. Urine samples were collected from 21 sows every third day from day 1 to 19 of lactation. Sows from this second group exhibited one of four distinct crosslinks excretion patterns: peak on day 1 (n = 3), peak on day 7 (n = 4), peak on day 10, 13 or 16 (n = 7), or no peak (n = 7). This variation of postpartum crosslinks excretion among sows was not related to parity, body weight, lactation body weight change, litter size, or litter birth weight. Overall, data from experiments I and II indicate that urinary HP does increase postpartum in a pattern temporally consistent with uterine involution. However, significant variation among sows in the magnitude and timing of peak HP excretion was evident.
Collapse
Affiliation(s)
- B A Belstra
- Department of Animal Science, North Carolina State University, Raleigh, NC 27695-7621, USA
| | | | | | | | | |
Collapse
|
5
|
Randle BJ, Scoltock SJ, Scott DK. Integrating molecular detection and response to create self-signalling antibodies. Biochem Biophys Res Commun 2004; 324:504-10. [PMID: 15474456 DOI: 10.1016/j.bbrc.2004.09.077] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2004] [Indexed: 11/17/2022]
Abstract
Monoclonal antibodies are reproducible, specific, and cost-effective molecular probes; use outside the laboratory is, however, restricted by technical limitations. Addressing these constraints, the first self-signalling antibodies are now described, where specific antigen binding causes release of bound reporter from bispecific antibodies (BsAb) to generate a detectable signal. The report examines the concept that two different antibody binding sites in close proximity can promote interaction between molecules recognised by these sites, generating a signal by molecular crowding. Signal strength is found to increase with increasing homogeneity for a BsAb reactive with multimeric surfactant antigen; signal response is linear for a BsAb reactive with univalent small analyte deoxypyridinoline. Self-signalling is consistent with intramolecular steric hindrance. This is the first report detailing integration of two different functions, molecular detection and signal response, into BsAbs and with detection of large and small analytes, has generic application to antibody-based systems.
Collapse
Affiliation(s)
- Beverley J Randle
- Antibody Research Laboratory, Division of Obstetrics, Department of Clinical Sciences at South Bristol, St. Michael's Hospital, University of Bristol, Bristol BS2 8EG, United Kingdom
| | | | | |
Collapse
|
6
|
Valtueña S, Cashman K, Robins SP, Cassidy A, Kardinaal A, Branca F. Investigating the role of natural phyto-oestrogens on bone health in postmenopausal women. Br J Nutr 2003; 89 Suppl 1:S87-99. [PMID: 12725658 DOI: 10.1079/bjn2002799] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Research on the bone effects of natural phyto-oestrogens after menopause is at a relatively early stage. Published studies are few, difficult to compare and often inconclusive, due in part to design weaknesses. Currently, many questions remain to be answered including to what extent a safe daily intake may prevent postmenopausal bone loss. These questions can only be addressed by conducting well-planned, randomised clinical trials that take into consideration present knowledge in the oestrogen, phyto-oestrogen and bone fields. This review is intended to provide hints for critical decision-making about the selection of subjects, type of intervention, suitable outcome measures and variables that need to be controlled.
Collapse
Affiliation(s)
- Silvia Valtueña
- Unit of Human Nutrition, National Institute for Research on Food and Nutrition, Via Ardeatina 546, I-00179 Rome, Italy
| | | | | | | | | | | |
Collapse
|
7
|
Abstract
PURPOSE OF REVIEW The primary aim of this review is to highlight recent advances in techniques available for assessing collagen turnover, particularly in relation to the diagnosis and management of bone disorders. As collagen is the major protein constituent of bone, its metabolites form the basis of most of the biochemical markers, but their efficacy needs to be viewed in the context of other non-collagenous markers, for which methodology is also advancing rapidly. RECENT FINDINGS New markers of bone metabolism have been developed utilising the age-dependent isomerisation and racemisation of aspartyl residues at the C-terminal end of collagen. These methods allow measurement of the ratio between newly synthesised and mature collagen: this ratio appears to provide a novel indicator of the fracture risk for osteoporosis. Other studies have led to an improved understanding of biological variability, particularly in relation to the effects of feeding. Bone resorption assays have been applied to a wide range of diseases and have been especially useful in monitoring the efficacy of novel therapies. SUMMARY New assays have been developed to facilitate better monitoring of collagen metabolism in bone diseases. A more complete understanding of biological variability, particularly the effects of feeding, have led to improved clinical applicability of these assays in detecting disease and monitoring therapy. Part of the future challenge, however, is to ensure that commercial assay developments keep pace with clinical expectations.
Collapse
Affiliation(s)
- Simon P Robins
- Matrix Biochemistry, Rowett Research Institute, Bucksburn, Aberdeen AB21 9SB, Scotland, UK.
| |
Collapse
|
8
|
Abstract
Molecular markers of bone turnover have gained increasing relevance in the evaluation of patients with metabolic bone diseases. Their clinical applications include the assessment of future osteoporotic fracture risk, complementation of bone density measurements, diagnosis of certain metabolic osteopathies, therapeutic decision making, and monitoring of therapeutic efficacy and patient compliance. One should be aware, however, that the results from large epidemiologic or clinical trials are sometimes difficult to translate into the everyday clinical situation. The individual patient often has more than one disease that might affect either bone turnover or the handling of the parameters mentioned (or both). Analytic and biologic variability of bone markers can be significant and also needs to be considered when using these indices. In the scientific setting, conventional and new markers of bone turnover can help to elucidate formerly unknown mechanisms and pathways. Because the development of ever more specific and sensitive markers of bone metabolism is progressing rapidly, we are likely to witness new insights into the pathophysiology of bone diseases in the near future.
Collapse
Affiliation(s)
- H W Woitge
- Department of Medicine, Endocrinology and Metabolism, University of Heidelberg, Heidelberg, Germany.
| | | |
Collapse
|
9
|
Adamczyk M, Johnson DD, Reddy RE. Bone collagen cross-links: a convergent synthesis of (+)-deoxypyrrololine. J Org Chem 2001; 66:11-9. [PMID: 11429886 DOI: 10.1021/jo0008901] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A convergent total synthesis of (+)-deoxypyrrololine (Dpl, 4), a putative cross-link of bone collagen, is described starting from a commercially available L-glutamic acid derivative, (4S)-5-(tert-butoxy)-4-[(tert-butoxycarbonyl)amino]-5- oxopentanoic acid (16). Condensation of aldehyde (S)-(-)-17 with nitro compound (S)-(-)-27, both of which were prepared from a common precursor (S)-16, gave the alpha-hydroxynitro compound 28, which upon acetylation afforded alpha-acetoxynitro compound 14 in good yield. Subsequent condensation and cyclization of alpha-acetoxynitro compound 14 with benzyl isocyanoacetate (15) in the presence of DBU in THF gave the key pyrrole intermediate (S,S)-(-)-12 in 57% yield. N-Alkylation of pyrrole (S,S)-(-)-12 with iodide (S)-(-)-13 using t-BuOK in THF afforded the 2-benzyloxycarbonyl-1,3,4-substituted pyrrole derivative (-)-29 in 42% yield. Removal of the protective groups in (-)-29 followed by hydrogenolysis and decarboxylation afforded the cross-link (+)-Dpl (4) in good overall yield. The synthesis of an analogue (S)-(+)-24 and formation of a novel tetrahydroindole derivative (-)-31 are also described.
Collapse
Affiliation(s)
- M Adamczyk
- Department of Chemistry (9NM, Bldg AP20), Diagnostics Division, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064-6016, USA.
| | | | | |
Collapse
|
10
|
Sarno M, Sarno L, Baylink D, Drinkwater B, Farley S, Kleerekoper M, Lang R, Lappe J, Licata A, McClung M, Miller P, Nattrass S, Recker R, Schwartz EN, Tucci JR, Wolf S, Powell H, Tjersland G, Warnick GR. Excretion of Sweat and Urine Pyridinoline Crosslinks in Healthy Controls and Subjects with Established Metabolic Bone Disease. Clin Chem Lab Med 2001; 39:223-8. [PMID: 11350019 DOI: 10.1515/cclm.2001.035] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Convenient techniques for measuring rates of bone turnover have been developed in recent years with the advent of biochemical markers of bone metabolism. One recent of these techniques is a collection method and quantitative enzyme immunoassay for free pyridinoline crosslinks in human sweat. The concentrations of pyridinoline crosslinks in 5-day sweat collections and first morning void and 24-hour urine collections from healthy subjects and subjects with established metabolic bone disorders were determined. T-scores were higher in the sweat system than in the urine system by up to 10-fold in postmenopausal subjects, women with hyperparathyroidism, and subjects with postmenopausal osteoporosis. For subjects with postmenopausal osteoporosis, receiver-operating characteristic curve analysis yielded areas under the curve of 0.699, 0.629, and 0.520 for sweat pyridinoline, first morning void urine pyridinoline, and 24 hour urine pyridinoline respectively. The areas under the curve of the sweat and first morning void urine measurements were significantly greater (p<0.05) than the 24-hour pyridinoline measurements. Healthy postmenopausal subjects and subjects with postmenopausal osteoporosis were monitored before and during estrogen replacement therapy or alendronate therapy. Sweat pyridinoline values declined by 49.0 +/- 12.4% and 19.4 +/- 19.9% for estrogen and alendronate subjects respectively. We conclude that this non-invasive technique is a sensitive and specific measure of bone resorption and is appropriate as an adjunct to techniques such as bone density and may also be useful in monitoring of response to anti-resorptive therapies.
Collapse
Affiliation(s)
- M Sarno
- Vision Biotechnology Consulting, Escondido, CA, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Allen MJ, Allen LC, Hoffmann WE, Richardson DC, Breur GJ. Urinary markers of type I collagen degradation in the dog. Res Vet Sci 2000; 69:123-7. [PMID: 11020362 DOI: 10.1053/rvsc.2000.0397] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Urinary assays for type I collagen metabolites provide a non invasive index of bone resorption in humans, and are widely used in the management of patients with metabolic bone diseases. The specific aims of this study were to investigate the feasibility of using commercial human assay kits for quantifying the urinary excretion of type I collagen metabolites in dogs of different ages. Urine and serum samples were collected from 35 beagle dogs in five age groups (0 to 1 years; 1 to 2 years; 2 to 3 years; 3 to 7 years; > 8 years old). Urinary concentrations of pyridinoline (Pyd), deoxypyridinoline (Dpd), and the carboxy- and amino-terminal cross-linked telopeptides of type I collagen (CTx and NTx, respectively) were measured with commercial enzyme-linked immunoassay kits. Serum concentrations of another type I collagen metabolite, the carboxy-terminal cross-linked teloptide of type I collagen (ICTP), were measured with a commercial radioimmunoassay. Dilutional studies indicated that the four urinary assays show specific cross-reactivity with canine urine. Age-related differences in urinary marker excretion were identified, with young dogs excreting the highest concentrations of Pyd, Dpd, NTx and CTx. The correlation between the individual urinary markers was excellent (r = 0.87 to 0.98), while the correlation between serum ICTP and individual urinary markers was weaker (r = 0.52 to 0.64). These results validate the usefulness of the commercial assay kits in monitoring type I collagen metabolism in dogs. Histomorphometric studies have confirmed the relationship between collagen degradation and bone resorption in humans, and similar studies are now needed in dogs.
Collapse
Affiliation(s)
- M J Allen
- Department of Orthopedic Surgery, SUNY-Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA
| | | | | | | | | |
Collapse
|
12
|
Woitge HW, Seibel MJ. Risk Assessment for Osteoporosis II: Biochemical Markers of Bone Turnover: Bone Resorption Indices. Clin Lab Med 2000. [DOI: 10.1016/s0272-2712(18)30050-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
13
|
Kindt E, Rossi DT, Gueneva-Boucheva K, Hallak H. Quantitative method for biomarkers of collagen degradation using liquid chromatography tandem mass spectrometry. Anal Biochem 2000; 283:71-6. [PMID: 10929810 DOI: 10.1006/abio.2000.4625] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Preclinical efficacy testing commonly involves studies that require considerable resources and time. One valuable tool in this endeavor is the characterization of relevant biomarkers. A method has been developed for the simultaneous determination of collagen biomarker candidates as an instrument in screening compounds for efficacy. Two potential candidates, the 3-hydroxypyridinium crosslinks pyridinoline and deoxypyridinoline, were selected for analysis in collagen degradation models. Tissue or urine samples were collected, prepared, and quantitated for the biomarkers using spiked calibration curves and liquid chromatography tandem mass spectrometry. The development of a quick and simple assay method would allow us to increase the chances for success in efficacy screening by eliminating compounds with poor biomarker profiles. The method proposed here appears to be more selective, convenient, precise (generally <10% RSD), accurate (generally <10% RE), and sensitive relative to previously established methodology.
Collapse
Affiliation(s)
- E Kindt
- Department of Pharmacokinetics, Dynamics, and Metabolism, Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan 48105, USA
| | | | | | | |
Collapse
|
14
|
Adamczyk M, Johnson D, Reddy R. Totalsynthese von (+)-Desoxypyrrololin: ein potentieller biochemischer Marker zur Diagnose der Osteoporose. Angew Chem Int Ed Engl 1999. [DOI: 10.1002/(sici)1521-3757(19991203)111:23<3751::aid-ange3751>3.0.co;2-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
15
|
|
16
|
Sarno M, Powell H, Tjersland G, Schoendorfer D, Harris H, Adams K, Ogata P, Warnick GR. A Collection Method and High-Sensitivity Enzyme Immunoassay for Sweat Pyridinoline and Deoxypyridinoline Cross-Links. Clin Chem 1999. [DOI: 10.1093/clinchem/45.9.1501] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Background: Collagen cross-link molecules such as pyridinoline (PYD), deoxypyridinoline (DPD), and N-terminal cross-linked peptides (NTX) have been measured in urine as indices of bone resorption. However, very little is known regarding the excretion of pyridinolines into other biological fluids. We report a collection device, normalizing analyte, and high-sensitivity immunoassay for quantitative analysis of free pyridinoline cross-links in sweat.
Methods: Flame atomic emission and ion-selective electrode techniques were used to measure potassium as a sweat volume marker. The Pyrilinks immunoassay for urine free pyridinolines was optimized to increase sensitivity for measurements in sweat. The precision, accuracy, and detection limit of this assay were characterized. To assess values and variability of sweat pyridinolines in human subjects, a nonocclusive skin patch was used to collect sweat samples from a reference group and from a mixed group experiencing accelerated bone resorption, postmenopausal women and men receiving gonadotropin-releasing hormone for prostate cancer.
Results: The immunoassay intra- and interassay variations were ≤10% and <16%, respectively, with a detection limit of 309 pmol/L. Linearity upon dilution and analytical recovery ranged from 93% to 109% and 85% to 122%, respectively. Sweat PYD values normalized to potassium output yielded a weekly intraindividual biological variability of 14.7%. The mean increase in the population experiencing increased bone resorption vs the reference group was 36% (P <0.05) for sweat PYD/K vs 23–40% (P <0.05) for urinary PYD/Cr, DPD/Cr, and NTX/Cr.
Conclusion: We conclude that this new platform sweat collection technology and PYD immunoassay show potential as an indicator of bone resorption.
Collapse
Affiliation(s)
- Mark Sarno
- Vision Biotechnology Consulting, 306-N W El Norte Pkwy., PMB 311, Escondido, CA 92026
| | - Helen Powell
- Pacific Biometrics, Inc., 220 West Harrison, Seattle, WA 98119
| | - Gayle Tjersland
- Pacific Biometrics, Inc., 220 West Harrison, Seattle, WA 98119
| | | | - Holden Harris
- Pacific Biometrics, Inc., 220 West Harrison, Seattle, WA 98119
| | - Kimberly Adams
- Pacific Biometrics, Inc., 220 West Harrison, Seattle, WA 98119
| | - Peggy Ogata
- Pacific Biometrics, Inc., 220 West Harrison, Seattle, WA 98119
| | | |
Collapse
|
17
|
Adamczyk M, Johnson DD, Reddy RE. A Convenient Method for Chemoselective O-Methylation of Hydroxypyridines. SYNTHETIC COMMUN 1999. [DOI: 10.1080/00397919908086473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
18
|
Bauer DC, Sklarin PM, Stone KL, Black DM, Nevitt MC, Ensrud KE, Arnaud CD, Genant HK, Garnero P, Delmas PD, Lawaetz H, Cummings SR. Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures. J Bone Miner Res 1999; 14:1404-10. [PMID: 10457273 DOI: 10.1359/jbmr.1999.14.8.1404] [Citation(s) in RCA: 117] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
To examine the ability of commercially available biochemical markers of bone formation and resorption to predict hip bone loss, we prospectively obtained serum and timed 2-h urine specimens from 295 women age 67 years or older who were not receiving estrogen replacement therapy. Serum was assayed for two markers of bone formation: osteocalcin (OC) and bone-specific alkaline phosphatase (BALP). Urine specimens were assayed for four markers of bone resorption: N-telopeptides (NTX), free pyridinolines (Pyr), free deoxypyridinoline (Dpyr), and C-telopeptides (CTX). Measurements of hip bone mineral density were made at the time the samples were collected and then repeated an average of 3.8 years later. Higher levels of all four resorption markers were, on average, significantly associated with faster rates of bone loss at the total hip, but not at the femoral neck. Women with OC levels above the median had a significantly faster rate of bone loss than women with levels below the median, but there was no significant association between levels of BALP and hip bone loss. The sensitivity and specificity of higher marker levels for predicting rapid hip bone loss was limited, and there was considerable overlap in bone loss rates between women with high and low marker levels. We conclude that higher levels of urine NTX, CTX, Pyr, Dpyr, and serum OC are associated with faster bone loss at the hip in this population of elderly women not receiving estrogen replacement therapy, but these biochemical markers have limited value for predicting rapid hip bone loss in individuals.
Collapse
Affiliation(s)
- D C Bauer
- Department of Medicine, University of California, San Francisco, San Francisco, California 94105, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Adamczyk M, Johnson DD, Reddy RE. Collagen cross-links: Synthesis of pyridinoline, deoxypyridinoline and their analogues. Tetrahedron 1999. [DOI: 10.1016/s0040-4020(98)01023-0] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
20
|
Miller PD, Baran DT, Bilezikian JP, Greenspan SL, Lindsay R, Riggs BL, Watts NB. Practical clinical application of biochemical markers of bone turnover: Consensus of an expert panel. J Clin Densitom 1999; 2:323-42. [PMID: 10548827 DOI: 10.1385/jcd:2:3:323] [Citation(s) in RCA: 95] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/04/1999] [Revised: 04/26/1999] [Accepted: 05/03/1999] [Indexed: 11/11/2022]
Abstract
Biochemical markers of bone turnover have emerged as powerful tools to aid in managing osteoporosis. The newer bone markers have been intensively studied for more than a decade. As a result, we can now confidently report their clinical utility in assessing risk of rapid bone loss and fracture, and monitoring therapy in postmenopausal women with or at risk of osteoporosis. In this review, we will provide a comprehensive foundation for this utility. While there are still questions remaining to be answered, bone marker technology has matured to play an essential role in patient management. We will describe, in practical terms, how bone markers can be appropriately incorporated into clinical practice today.
Collapse
Affiliation(s)
- P D Miller
- Department of Medicine, University of Colorado Health Sciences Center and Colorado Center for Bone Research, Denver, CO 80227, USA.
| | | | | | | | | | | | | |
Collapse
|
21
|
Seibel MJ, Woitge HW. Basic principles and clinical applications of biochemical markers of bone metabolism: biochemical and technical aspects. J Clin Densitom 1999; 2:299-321. [PMID: 10548826 DOI: 10.1385/jcd:2:3:299] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/18/1999] [Revised: 04/23/1999] [Accepted: 04/26/1999] [Indexed: 01/12/2023]
Abstract
The interest in and the need for effective measures to be used in the screening, diagnosis, and follow-up of disorders of connective tissue, bone, and mineral metabolism has markedly grown. Next to clinical and imaging techniques, indices of bone turnover have come to play an important role in the assessment of metabolic bone disease. In osteoporosis, recent research has shown that bone markers may also be used to predict future bone loss and hip fractures (in larger cohorts of older patients), identify individuals at risk for osteoporosis, select therapy, and predict and monitor the therapeutic response in individual patients. The development of new markers of bone metabolism has greatly enriched the spectrum of serum and urine analytes used in the assessment of skeletal pathologies. Besides total alkaline phosphatase, other markers such as bone-specific alkaline phosphatase, osteocalcin, or the collagen propeptides are being used to measure bone formation. Bone resorption, previously assessed only by the measurement of urinary calcium and hydroxyproline, may now be detected more precisely by a number of new serum and urine markers. Among these, the pyridinium crosslinks and the telopeptides of collagen type I are presently considered the most specific markers of bone resorption. More recently, bone sialoprotein has also been suggested as a marker of bone resorption in serum. Tartrate-resistant acid phosphatase is now measurable by immunoassay. This article surveys the biochemistry and relevant technical aspects of the currently available markers of bone metabolism.
Collapse
Affiliation(s)
- M J Seibel
- Department of Internal Medicine I, Division of Endocrinology and Metabolism, University of Heidelberg, 69115 Heidelberg, Germany.
| | | |
Collapse
|
22
|
Fermo I, Arcelloni C, Casari E, Paroni R. Urine Pyridinium Cross-Links Determination by Beckman Cross Links Kit. Clin Chem 1997. [DOI: 10.1093/clinchem/43.11.2186] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
23
|
Clemens JD, Herrick MV, Singer FR, Eyre DR. Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem 1997. [DOI: 10.1093/clinchem/43.11.2058] [Citation(s) in RCA: 132] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Abstract
Previous studies have shown that immunoassay of urinary NTx (cross-linked N-telopeptides of type I collagen) provides a responsive index of human bone resorption. Here we report by a sensitive immunoassay that NTx is present in serum and is suppressed appropriately in patients with Paget disease of bone by bisphosphonate antiresorptive therapy. The monoclonal antibody (1H11) developed against urinary NTx was applied in a sensitive chemiluminescence format. Results for human serum and urine showed parallel inhibition curves. The NTx concentrations in paired serum and urine samples from individual patients correlated well when urinary concentrations were normalized to creatinine concentrations (in premenopausal and postmenopausal women and Paget disease patients, r = 0.90, n = 60). The percentage of NTx suppression from baseline values for Paget disease patients on bisphosphonate therapy was similar for serum and urine. Blood samples drawn from bone marrow at the site of Pagetic lesions in three patients with active disease had as much as 10-fold higher concentrations of NTx than did peripheral blood samples drawn at the same time. The latter finding is consistent with other evidence showing that immunoreactive NTx originates directly during the proteolytic cleavage of bone collagen by osteoclasts rather than, e.g., by degradative processes occurring later in the liver and kidney.
Collapse
Affiliation(s)
- J Daniel Clemens
- Ostex International, Inc., 2203 Airport Way South, Suite 400, Seattle, WA 98134
| | - Michael V Herrick
- Ostex International, Inc., 2203 Airport Way South, Suite 400, Seattle, WA 98134
| | | | - David R Eyre
- Orthopedic Research Labs, University of Washington, Seattle, WA
| |
Collapse
|